On-Demand CME Videos
Open Up to New Treatments for Vitiligo: Online CME Activity
This activity was recorded at the Winter Clinical Dermatology Conference-Hawaii on January 17, 2023
CME Seminar in Depth - Open Up to New Treatments for Vitiligo
This activity is supported by an educational grant from Incyte.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
January 17, 2023
January 17, 2024
At the completion of this activity, participants should be better able to:
Recall the clinical trial data on JAK inhibitors for the management of vitiligo
Describe strategies to manage AE associated with JAK inhibitors
Discuss how to utilize JAK inhibitors in clinical practice for the management of vitiligo
Seemal Desai, MD
Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
Susan Taylor, MD
Incoming President-elect, American Academy of Dermatology
Bernett L. Johnson Endowed Professor in Dermatology
Perelman School of Medicine, University of Pennsylvania
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: AbbVie, Incyte, Dermavant, AOBiome,
Consultant: Galderma, Almirall, Ferndale, BMS, AbbVie, Verrica, UCB, Ortho, Scientis, EPI, Avita, Eli Lilly, Leo, Pfizer, Incyte, L’Oreal, Beiersdorf, J&J
Speakers’ Bureau or Honoraria: Dermavant, Galderma, Pfizer
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.